Latest Conference Articles

In a new study conducted in Taiwan, investigators found that use of metformin to treat diabetes also reduced the risk of AMD development over a 13-year period.

In patients with neovascular AMD, 24% receiving brolucizumab had intra-retinal fluid and/or sub-retinal fluid compared to 37% of aflibercept-treated patients in the HAWK trial.

Peter Campochiaro, MD, professor of ophthalmology and director of the retinal cell and molecular laboratory at Johns Hopkins explains the burdens of receiving frequent anti-VEGF injection treatments.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months was 1.3 in a phase 1 cohort study.

R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 1 trial, patients in the femto-assisted crosslinking treatment arm had a more favorable outcome in the retention of corneal thickness, when compared to the conventional therapy group.

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 months before requiring a refill.

A team of investigators has found that collaborative efforts among several leading medical institutions have helped increase the study of new medications for myelodysplastic syndromes (MDS).

A panel of members from the US Food and Drug Administration (FDA) sat down to discuss the influential factors and projective trajectory of the rare disease pipeline.

RT001 has demonstrated arrest of disease progression in 2 patients with infantile neuroaxonal dystrophy.

Members from the FDA came together to participate in an informative session and discuss the traditional pathway and future outlook of clinical trials in rare diseases.

Ellen Sigal, PhD, discusses how she helped make the concept of the expedited FDA development program a reality.

Karlyne Reilly, PhD, discusses the Rare Tumor Patient Engagement Network and the importance of getting patients with rare conditions involved in cancer research.

Receiving a proper diagnosis can be one of the greatest challenges for a rare disease patient, but having the right tools can help.

Though new therapies are still in the distant future, advances in diagnosis may be on the horizon.

John Hopper, MBA, highlights advances made in the fight against rare cancers and discusses what’s next for the community.

Although there have been many successes experienced in the oncology community, more genomic data is needed.

A panel at the NORD 2018 Summit discusses how patients are the catalysts behind rare disease research and drug development.

William A Gahl, MD, PhD, discusses challenges associated with diagnosing rare diseases and how health care providers might overcome them.

Distinguishing pulmonary arterial hypertension in patients is a difficult early diagnosis. But seeking out a combination of unexplained symptoms is a good first step.

Experts advise that primary care physicians give pause next time they treat a patient with unexplained dyspnea—could it be pulmonary hypertension?

Though the commonly accepted ratio is 3:1 women, longtime clinicians suggest PAH ratio is more likely closer to 4:1.

Findings indicate that treatment interruptions are possible, with caveats.

Mary Beth Scholand, MD, outlines the best treatment practices for idiopathic pulmonary fibrosis (IPF) to date and therapies worth investigating in the future.

Nicola Hanania, MD, MS, director of the Airways Clinical Research Center at Baylor College of Medicine, explains the latest research on COPD treatments and outlines how they all measure.

The 2019 CHEST Meeting in New Orleans may be headlined by newly approved therapies including dupilumab and tezepelumab.